AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions.

AbbVie ABBV reported 9% revenue growth in 2025 and provided 2026 guidance of $67 billion in revenue (10% growth) and a ...

AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported ...

AbbVie Inc. Q4 2025 shows SKYRIZI/RINVOQ strength but diversification risks and M&A reliance. Click here to read this earnings analysis of ABBV stock.

Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results ...

Despite AbbVie exceeding expectations for the last year and its forecast for 2026, its stock still fell in trading this morning as investors zeroed in on vulnerabilities in its tentpole drugs.

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.

AbbVie Inc. forecast 2026 profits above Wall Street’s expectations, though investors saw vulnerabilities in some of the ...

Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...

Looking ahead, AbbVie's full-year 2026 adjusted earnings guidance is $14.37-$14.57 per share, above the analyst consensus of ...

Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...